API
< Back to all clusters
[BUSINESS] · Australia, United States, Germany, Japan · 2 sources

started · updated

Neuren Pharmaceuticals shares rise on strong Daybue sales and milestone payment

Neuren Pharmaceuticals shares rose nearly 17% on Thursday, reaching a 12-month high, following strong third-quarter sales of Daybue, a drug used to treat Rett syndrome. The company reported that Daybue net sales reached US$140 million, a 39% increase compared to the same period last year.

Driven by robust sales from its US partner, Acadia Pharmaceuticals, Neuren increased its full-year 2026 royalty income guidance to a range of US$56 million to US$58 million. The company also secured a US$35 million milestone payment following the launch of Daybue in Germany in October.

Additionally, Neuren strengthened its intellectual property position with the allowance of a new US patent covering weight-banded dosing of trofinetide, which extends protection until March 2041. The company is also pursuing regulatory approval for the drug in Japan.

Entities

Acadia Pharmaceuticals · DAYBUE · Jon Pilcher · Neuren Pharmaceuticals